FATE Therapeutics, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 200
Rang # Quantité totale PI 6 524
Note d'activité PI 3/5.0    142
Rang # Activité PI 4 848
Symbole boursier
ISIN US31189P1021
Capitalisation 309M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

72 8
36 3
76 4
1
 
Dernier brevet 2025 - Ipsc-derived t cells for solid t...
Premier brevet 2008 - Methods for reprogramming cells ...
Dernière marque 2023 - TOLERACYTE
Première marque 2009 - FATE THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Enhanced immune effector cells and use thereof. Provided are methods and compositions for obtain...
2024 Invention Ipsc-derived t cells for solid tumor treatment. Provided are methods and compositions for use in ...
Invention Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors. Provided ...
Invention Compositions and methods for muscle disorders. The invention discloses approaches to correct DUX-...
Invention Ipsc-derived effector cells for autoimmune disease treatment. Provided are methods and compositio...
Invention Liver detargeted capsids. The present invention provides novel capsid variants for viral vectors ...
Invention Solid tumor targeting backbone promoting effector cell differentiation and function. Provided are...
Invention Aav gene therapy approach for treating lgmd2b/dysferlinopathy. This disclosure relates to composi...
Invention Ipsc-derived nk cell for lymphoma treatment. Provided are methods and compositions for use in can...
Invention Compositions and methods for immune cell modulation in adoptive immunotherapies. Compounds that ...
Invention Muscle targeted capsids. The present invention provides novel capsid variants for viral vectors t...
2023 Invention Ipsc-derived nk cell targeting mica/b for solid tumor treatment. Provided are methods and composi...
Invention Composition and methods for inducing myeloid suppressive cells and use thereof. Compositions and...
Invention Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b. . Provide...
Invention Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d. Provided...
Invention Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2. Pr...
P/S Stem cells for medical purposes; therapeutic cell preparation for the treatment of auto-immune di...
Invention Methods and compositions for inducing hematopoietic cell differentiation. In various aspects, the...
Invention Methods and compositions for inducing hematopoietic cell differentiation
Invention Chimeric antigen receptor for tumor targeting. Provided are chimeric antigen receptors (CAR) spec...
Invention Cells having solid tumor targeting backbone and use thereof. Provided are methods and composition...
Invention Enhancing effector cell durability and efficacy in adoptive cell therapies. Provided are methods ...
Invention Enhancing effector cell durability and efficacy in adoptive cell therapies
Invention Compositions for treating xlmtm. The present invention provides a novel muscle-tropic viral vecto...
Invention Stealth strategy engaging immune recognition pathways for use in allogeneic cell therapies. Provi...
Invention Compositions and methods for muscle disorders. The invention discloses approaches to reduce expre...
Invention Methods and compositions for inducing hematopoietic cell differentiation. The invention provides...
2022 Invention Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors. Provide...
Invention Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors. Provided...
Invention Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors. Provided ...
Invention Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors. Provided...
P/S Therapeutic cell preparations based on NK cells (natural killer cells) for the treatment of cance...
Invention Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody. Provided...
Invention Protected effector cells and use thereof for allogeneic adoptive cell therapies. Provided are me...
2021 Invention Off-the-shelf ipsc-derived nk cell therapy for hematological cancer treatment. Provided are meth...
Invention Engineered ipsc and immune effector cells for heterogenous tumor control. Provided are methods a...
Invention Engineered ipsc and persistent immune effector cells. Provided are methods and compositions for ...
Invention Multiplexed engineered ipscs and immune effector cells targeting solid tumors. Provided are meth...
Invention Engineered ipsc and armed immune effector cells. Provided are methods and compositions for obtai...
Invention Improved reprogramming, maintenance and preservation for induced pluripotent stem cells. Provide...
Invention Combining ipsc derived effector cell types for immunotherapy use. Provided are methods and compos...
P/S Cells for medical purposes; therapeutic preparation for the treatment of disease and immune disor...
2020 Invention Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof. Provide...
Invention Vial rack
2017 P/S Cells and pharmaceutical preparations for the treatment of diseases, namely hematopoietic cells f...
P/S Cells for medical purposes; therapeutic preparation for the treatment of disease and immune diso...
P/S Cells and pharmaceutical preparations for the treatment of diseases; bio-engineered component fo...
2016 P/S Reagents for research, drug discovery and development, and clinical laboratory use Pharmaceutical...
P/S Medical and clinical research and development for others in the field of stem cells; consulting s...
P/S Pharmaceutical preparations and therapeutic agents to modulate cell function or cell fate; reagen...
2013 P/S Pharmaceutical preparations and therapeutic agents to modulate stem cell pathways to promote heal...
2012 P/S Stem cells for medical purposes; therapeutic preparation for the treatment of diseases.
2010 P/S medical and clinical research and development for others in the field of stem cells; consulting s...
2009 P/S Reagents for research, drug discovery and development in the field of stem cells and small molecu...
P/S Pharmaceutical preparations and therapeutic agents; pharmaceutical preparations and therapeutic ...
P/S pharmaceutical preparations and therapeutic agents to modulate cell fate; reagents for research, ...